Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model

Osimertinib is a third-generation, irreversible, oral EGFR tyrosine kinase inhibitor (TKI) recommended as first-line treatment for patients with locally advanced/metastatic EGFR mutation–positive (EGFRm) non–small cell lung cancer (NSCLC). However, MET amplification/overexpression is a common acquir...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Rhys D.O., Petersson, Klas, Tabatabai, Areya, Bao, Larry, Tomkinson, Helen, Schuller, Alwin G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Models and Technologies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157363/
https://www.ncbi.nlm.nih.gov/pubmed/36888921
http://dx.doi.org/10.1158/1535-7163.MCT-22-0193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157363/
https://www.ncbi.nlm.nih.gov/pubmed/36888921
http://dx.doi.org/10.1158/1535-7163.MCT-22-0193

Ejemplares similares